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Abstract
Background: Intermittent preventive treatment in infants with sulphadoxine-pyrimethamine (IPTi-SP) reduces
malaria morbidity by 20% to 33%. Potentially, however, this intervention may compromise the acquisition of
immunity, including the tolerance towards multiple infections with Plasmodium falciparum.
Methods: Plasmodium falciparum isolates were obtained from children participating in two Ghanaian IPTi-SP trials
(Tamale, Afigya Sekyere) at 15 months of age, i.e., six months after they had received the second dose of IPTi-SP or
placebo. By typing the polymorphic merozoite surface protein 1 (msp1) and msp2 genes, multiplicity of infection
(MOI) was assessed in 389 isolates. A total of additional 133 samples were collected in Tamale at 3, 6, 9, and
12 months of age. Comparisons of MOI between groups were done by non-parametric statistical tests.
Results: The number of distinguishable P. falciparum clones (MOI) ranged between one and six. Mean MOI in
Tamale was stable at 2.13 - 2.17 during the first year of life, and increased to 2.57 at age 15 months (P = 0.01).
At no age did MOI differ between the IPTi-SP and placebo groups (each, P ≥ 0.5). At 15 months of age, i.e., six
months after the second dose, MOI was very similar for children who had received IPTi or placebo (means, 2.25 vs.
2.33; P = 0.55) as was the proportion of polyclonal infections (69.6% vs. 69.7%; P = 0.99). Adjusting for study site,
current and prior malaria, parasite density, and season did not change this finding.
Conclusions: IPTi-SP appears to have no impact on the multiplicity of infection during infancy and thereafter. This
suggests that tolerance of multiple infections, a component of protective immunity in highly endemic areas, is not
affected by this intervention.
Background
Efficient and safe means of controlling falciparum
malaria in endemic areas are urgently needed to reduce
its intolerable high burden, particularly in young chil-
dren. Reducing parasite exposure, however, may com-
promise the acquisition of protective immunity, as has
been debated with respect to vector control and was
observed following chemoprophylaxis [1-3].
Multiplicity of infection (MOI) denotes the number
of distinguishable Plasmodium falciparum clones per
isolate. Commonly, MOI is assessed by using the
polymorphic regions of P. falciparum merozoite surface
proteins 1 and 2 genes (msp 1/2)a sm a r k e r s .I nt h a t ,
inter-laboratory differences exist [4], and methods dis-
playing higher parasite diversity have been developed
[5]. Irrespective of that, MOI has been considered to be
subject to and to form part of the complex immune
mechanisms in malaria. In children intensely exposed to
antigenically diverse parasites, MOI is considered to
roughly indicate the extent of acquired immunity by
reflecting tolerance to multiclonal infections. These, in
turn, may stimulate and maintain cross-protective
immune responses [6,7]. The association between MOI
and the subsequent risk of malarial disease is intricate
and depends on, e.g., age and transmission intensity. At
intense transmission, MOI increases in parallel to the
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parasitaemia [6]. Indeed, among older children living in
these areas, high MOI has repeatedly been associated
with protection from subsequent clinical episodes
[7-12]. In contrast, P. falciparum infections of compara-
tively short duration in infants preclude tolerance [13],
and multiclonal infections rather increase the risk of
clinical attacks [14-16]. The latter is also observed in
areas of moderate transmission [7,16,17].
Intermittent preventive treatment in infants (IPTi)
denotes the administration of a curative dose of an anti-
malarial, commonly sulphadoxine-pyrimethamine (SP)
at the times of routine vaccination, regardless of
whether a child is parasitaemic or not. IPTi with SP
(IPTi-SP) was initially tested in Tanzania also as an
approach to avoid the rebound effect of increasing mor-
bidity following chemoprophylaxis. In that initial study,
IPTi-SP reduced the incidence of malaria in infancy by
59% without evidence of a rebound effect [18]. In five
subsequent trials using slightly different treatment sche-
dules, this protective efficacy ranged between 20% and
33% [19-23]. Overall, IPTi-SP in these six trials in Tan-
zania, Mozambique, Ghana and Gabon had a protective
efficacy against clinical malaria of 30% in the first year
of life [24]. Evidence for a rebound of malaria (high den-
sity parasitaemia, severe malaria) in the second year of
life was observed in two studies [19,22]. Meanwhile,
IPTi has been tested at further sites and using different
drugs [25,26], and WHO considers IPTi for implemen-
tation in areas of moderate to high transmission and
where SP resistance is not high [27].
So far, only scarce data are available on the effect of
anti-malarial interventions on MOI. In Tanzania, MOI
was significantly reduced among infants infected despite
chemoprophylaxis and this reduction was suggested to
be involved in the subsequent rebound in clinical
malaria episodes [28]. RTS, S vaccination reduced MOI
in Mozambique and Kenya [29,30] whereas insecticide-
treated nets (ITNs) left MOI virtually unchanged in
Tanzania [31]. Here, in two Ghanaian IPTi cohorts, a
potential sustained impact of IPTi on multiclonal infec-
tions was examined by assessing MOI in infected chil-
dren six months after they received their second dose of
IPTi-SP.
Methods
Plasmodium falciparum isolates obtained from children
participating in two related, randomized IPTi trials con-
ducted in Tamale, hyperendemic northern Ghana, and
in Afigya Sekyere district, holoendemic southern Ghana,
were examined. The attempt of identical examinations
in the IPTi trial from Lambaréné, Gabon [23], was aban-
doned because of scarce availability of positive samples
precluding a meaningful analysis. The study protocols
were reviewed and approved by the Ethics Committees,
University for Development Studies, Tamale, Kwame
Nkrumah University of Science and Technology,
Kumasi, and International Foundation of the Albert
Schweitzer Hospital, Lambaréné, and informed consent
was obtained from the children’s parents. Details of the
site characteristics and the analysed two trials have been
presented elsewhere. The trial in Tamale was performed
from March 2003 through July 2005, and the one in Afi-
gya Sekyere from January 2003 through September 2005
[21,22]. Briefly, while Tamale is a city of some 350,000
inhabitants but of rather rural character, the study in
Afigya Sekyere comprised nine villages of 1,500 to
13,000 inhabitants. Malaria transmission is perennial
with seasonal variation at both sites; entomologic data
are not available for Tamale but in Afigya Sekyere,
approximately 400 infective bites per person-year were
observed in 2003-2005 (unpublished data). Coverage
with insecticide-treated bed nets was low at ≤3% in both
sites in 2003-2005 [21,22]. In the first year of life, the
incidence of malaria has been estimated as 0.95 and
1.27 episodes per person-years at risk in Tamale and
Afigya Sekyere, respectively [24]. In the two IPTi trials,
2270 children were recruited at three months of age and
followed up actively in three-monthly (Tamale) or
monthly (Afigya Sekyere) intervals, and passively, until
24 months of age. IPTi-SP or placebo was administered
at ages 3, 9, and 15 months. Active follow-up included
clinical examination, regular blood sampling, and parasi-
tological and haematological examinations. During pas-
sive follow-up visits, i.e. when patients presented
independently from regular visits, identical procedures
were done as detailed elsewhere [21,22]. Episodes of
malaria were treated with artesunate (4 mg/kg, double
dose on first day, for five days, Tamale) or amodia-
quine-artesunate (10/4 mg/kg for three days, Afigya
Sekyere). A sample size of ≥1,070 infants in each trial
was estimated to provide 80% power for detecting a 20%
reduction of hazards of developing malaria in the SP
group, compared with the placebo group [21,22].
On the day of IPTi dose-3, i.e., six months following
IPTi dose-2 and at approximately 15 months of age,
venous blood samples were collected. These were stabi-
lized by adding an equal volume of DNA-stabilizing buf-
fer (AS1, Qiagen, Germany), stored at +4°C, and DNA
was extracted by commercial kits (QIAmp, Qiagen, Ger-
many). All samples with microscopically confirmed P.
falciparum parasitaemia were subjected to assessing
MOI. For that, sequences corresponding to the allelic
families of P. falciparum msp1 block 2 (K1, Mad20,
Ro33) and of msp2 block 3 (FC27, IC) were amplified in
five separate nested PCR assays [32]. These alleles are
characterized by conserved regions flanked by repeat
sequences of variable length. Therefore, size variation
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parasite clones by PCR fragment length polymorphism.
Fragments were separated on 3% GTG®-agarose gels
(Biozym, Germany) and analysed using GeneSnap soft-
ware (SynGene, UK). In case of negative or inconclusive
PCR results, assays were repeated maximally twice. MOI
was calculated as the highest number of fragments for
either msp1 or msp2. Of a total of 348 microscopically
positive samples collected at 15 months of age, MOI
could be assessed in 277 (79.6%). For the Tamale trial,
all samples collected at 15 months of age were examined
by Plasmodium-specific nested PCR assays [33] and
msp1/2 genotyping was extended to additional 142 sam-
ples identified to have submicroscopic parasitaemia of
which 112 yielded a result for MOI (typing efficiency,
78.9%). Also, for the Tamale cohort, a random sample
of microscopically positive samples (if available, each 25
for placebo and IPTi-SP groups) collected at 3, 6, 9, and
12 months of age was genotyped to illustrate the devel-
opment of MOI with age (typing efficiency, 72.2%). For
all samples, processing and DNA extraction were per-
formed in a standardized manner, and all samples were
typed at the Institute of Tropical Medicine in Berlin,
Germany.
Malaria was defined by the presence of microscopi-
cally visible parasitaemia plus fever (axillary tempera-
ture, ≥37.5°C, or, Afigya Sekyere, ≥38.0, <12 months,
rectally; ≥12 months, tympanically) or fever during the
preceding 48 hours reported by mothers without being
asked. For incidence estimates, children were regarded
as not being at risk for 21 days following an episode of
malaria and person-time-at-risk was reduced accord-
ingly. Polyclonal infections had a MOI of >1. Rainy sea-
son (> 10 days or >90 mm of precipitation/month) was
defined as before [5,22].
Continuous parameters were compared between
groups by the non-parametric Mann-Whitney U-test or
Kruskal-Wallis test. These tests were also applied to
compare MOI between groups but results are primarily
presented as arithmetic means since this measure of
average more selectively displays (the direction of) dif-
ferences than medians, which are also shown, neverthe-
less. Proportions of polyclonal infections were analysed
by c
2 tests. In multivariate analysis, known or potential
confounders of the proportion of polyclonal infections
and MOI were adjusted for by including these in logistic
regression models and by applying non-parametric mul-
tiple ordinal regression, respectively.
Results
The characteristics of the 1086 children at 15 months of
age from Tamale and their 964 peers from Afigya
Sekyere are shown in Table 1. As compared to children
from Tamale, their peers from Afigya Sekyere showed
more microscopically determined parasitaemia, more
frequently had a current episode of malaria but less fre-
quently were febrile or anaemic. Also, more children
from Afigya Sekyere than from Tamale had had malaria
until 15 months of age, and the number of previous epi-
sodes was higher. Most children in Tamale had their
scheduled visit at 15 months of age during the rainy sea-
son, but only roughly half in Afigya Sekyere (Table 1).
In Tamale and Afigya Sekyere, IPTi-SP at ages 3 and
9 months had achieved reductions in the incidence of
malaria until 15 months of age of 24% (13-33%) and
20% (95%CI, 12-28%), respectively, largely due to inci-
dence reductions during the first month following each
treatment [21,22,24]. At 15 months of age, no impact of
previous IPTi-SP on malariometric parameters was dis-
cernible: children who had received IPTi-SP or placebo
showed similar prevalences of asymptomatic parasitae-
mia (16.9% (172/1015) vs. 17.4% (176/1013), P =0 . 8 0 )
and malaria (9.6% (97/1015) vs. 8.9% (90/1013), P =
0.60). Also, GMPDs (95%CI) were alike (1622 (1175-
2238) vs. 1791 (1318-2432)/μL, P = 0.66).
The development of MOI with age in Tamale is
shown in Figure 1. Overall, MOI was stable at a mean
of 2.13 - 2.17 (medians, each 2) during the first year of
life (P = 1.0), and increased to 2.57 (median, 2; range
1-5) at age 15 months (P = 0.01). At no age, did MOI
differ between IPTi-SP and placebo groups (P ≥ 0.5).
Lacking impact of IPTi-SP on MOI was confirmed
when adjusting for parasite density and age by multiple
ordinal regression (P = 0.32; Figure 1).
At 15 months of age, a total of 277 samples with
microscopically visible parasitaemia were successfully
genotyped, comprising 163 (58.8%) samples of malaria
cases. The distribution of MOI in these 277 samples is
shown in Figure 2. Further 112 specimens of submicro-
scopic infections were available from Tamale. Irrespec-
tive of study site, MOI (mean, 2.29; median, 2; range, 1-
6) and the proportion of polyclonal P. falciparum infec-
tions (69.7%) were similar among former IPTi-SP and
placebo recipients. This was true for both microscopi-
cally identified and submicroscopic infections (Table 2).
Known factors influencing multiplicity and potential
confounders were tested (Table 3): MOI (and polyclonal
infections) in microscopically positive samples were
increased in children with current malaria, tended to be
higher in Tamale than in Afigya Sekyere, and increased
with parasite density (Table 3). Prior occurrence of
malaria was not associated with MOI itself but, at bor-
derline significance, with less polyclonal infections.
A lowered multiplicity of P. falciparum in the rainy sea-
son was observed only in multivariate analysis. Adjusting
for these factors, the finding that previous IPTi-SP did
not influence the multiplicity of P. falciparum infection
was confirmed (Table 3).
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showed a lesser multiplicity than those microscopically
visible (mean MOI, 2.02 vs. 2.57; medians (range), each
2( 1 - 5 ) ;P = 0.0006). Submicroscopic infections were
arbitrarily set as 1 parasite/μL and included into a sepa-
rate multivariate analysis as above for the Tamale
cohort. Again, no significant impact of IPTI-SP on MOI
(regression coefficient, -0.15; standard error, 0.36; P =
0.67) or on polyclonal infections (adjusted OR, 1.03;
95%CI, 0.56-1.87, P = 0.93) was discernible.
Between months 16 and 24 of follow-up of the Tamale
cohort, 12 excess cases of severe malaria were observed
in the previous IPTi group [22]. For the six of these
12 children for whom genotyping data were available at
15 months of age, MOI did not differ from the remain-
ing 100 children in the IPTi group (means, 2.00 vs. 2.23;
medians (range), 2 (1-5) vs. 2 (1-3); P = 0.82).
Discussion
In holoendemic Tanzania, continuous chemoprophylaxis
in infancy reduced the multiplicity of infection with
P. falciparum, and the rebound of malaria following that
intervention has been attributed to this reduction [28].
In the present analysis of two IPTi-SP cohorts from
hyper- and holoendemic Ghana, no evidence was found
that this intervention has a sustainable effect on multi-
plicity. This finding supports the principle idea of IPTi,
i.e. a basically chemoprophylactic intervention of limited
duration [21,22,24,34] allowing for sufficient exposure to
develop and maintain immunity. In consequence also,
because IPTi-SP did not affect multiplicity which has
been linked to prospective risks of malaria [7-17] this
study does not support the attribution of potential
rebound effects to interference with MOI. In particular,
in the Tamale cohort, rebound events in the former
IPTi-SP recipients were not associated with MOI at
15 months. Admittedly, however, only few samples were
available for analysis, and most children with later
severe malaria were not infected at that time.
The present study analysed multiplicity only, i.e. one
actor in the network of diverse immune mechanisms.
The importance of this factor is furthermore varying
with age and endemicity [7-17]. Also, the single
Table 1 Characteristics of 2050 Ghanaian children at 15 months of age, i.e. six month after the third dose of IPTi-SP
Parameter Tamale Afigya Sekyere P
No. 1086 964
Proportion girls (%) 50.2 49.3 0.68
Examination for present study (15 months of age) in rainy season (%) 89.6 49.3 < 0.0001
SP group : placebo group 542 : 544 485 : 479 0.86
Current P. falciparum infection
by microscopy (%; n/n) 11.0 (119/1084) 24.3 (229/944) < 0.0001
GMPD (parasites/μL, 95%CI) 2312 (1599-3344) 1455 (1105-1917) 0.03
by PCR (%) 23.6 (248/1049) n.a. -
Current malaria episode (%, n/n) 7.4 (80/1084) 11.3 (107/944) 0.002
Febrile (%, n/n) 12.8 (138/1082) 6.1 (59/964) < 0.0001
History of fever within 48 h (%, n/n) 31.7 (344/1086) 31.8 (307/964) 0.93
Haemoglobin (g/dL; mean, range) 8.91 (4.7-12.7) 9.90 (2.0-15.0) < 0.0001
Proportion anaemic (Hb < 11 g/dL; %, n/n) 94.0 (1019/1084) 74.4 (715/961) < 0.0001
Proportion severely anaemic (Hb < 7 g/dL; %, n/n) 8.0 (87/1084) 4.9 (47/961) 0.004
Proportion with prior episode(s) of malaria (%, n/n) 47.4 (515/1086) 57.6 (555/964) < 0.0001
No. of previous malaria episodes (mean, range) 0.67 (0-5) 1.23 (0-7) < 0.0001
GMPD, geometric mean parasite density; Hb, haemoglobin; n.a., not available
Figure 1 Multiplicity of infection and geometric mean parasite
density according to age. Group sizes at ages 3, 6, 9, 12, 15
months: 15, 38, 44, 36, 104. Parasite density declines until 12
months of age and slightly increases thereafter (P = 0.08). IPTi had
no effect on parasite density (P = 0.57), at no time (P > 0.4). In
multiple, non-parametric ordinal regression analysis, IPTi had no
effect on MOI in these children (regression coefficient, -0.33;
standard error (SE), 0.33; P = 0.32; age (months), 0.06, SE, 0.06;
P = 0.30; log10 parasite density, 0.78, SE, 0.19; P < 0.0001).
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only a still image of an actually dynamic parasite com-
p o s i t i o n[ 3 5 ] .D a t aw e r ed erived exclusively from
infected children, i.e., the minority of individuals under
study. Typing efficiency was at the lower range of pre-
viously reported results [4]. Thus, a proportion of chil-
dren who were infected, presumably at very low parasite
densities, could not be included into the analysis. The
risk of malaria at a given time is determined by a multi-
tude of factors including among others, host heteroge-
neity and temporal variation in exposure, genetics,
socio-economic status, and treatment-seeking behaviour
[36,37] which, however, due to randomization should be
evenly distributed between the placebo and IPTi groups.
Thus, as one limitation of the present study, the results
are valid only for those children harbouring parasites on
examination, and the influence of other factors on
malaria and malarial immunity may outweigh the one of
multiplicity of infection.
The present data accord with previous findings from
highly endemic areas [13,14] in that MOI was basically
stable throughout the first year of life and increased
only at its end. Paralleled by the increasing ability to
control parasitaemia (Figure 1) this may indicate a
change of the predominant type of host response at this
age. While in infancy infections are rather short-lived
[13] and fever and pro-inflammatory responses are the
main defence armamentarium [38], the development of
tolerance to the establishment and persistence of (low-
grade) parasitaemia, i.e. premunition, is considered a
prerequisite for clinical immunity [6]. However, it
should be noted MOI is also interpreted alternatively,
namely as a parameter of (recent) accumulation of infec-
tions, higher exposure, and possibly increased malaria
incidence rather than a proxy parameter for premuni-
tion [16,35]. Obviously, MOI is a highly complex para-
meter and subject to various inter-related influences. Of
note, the temporal dynamics of P. falciparum infection
also affect the assessment of parasite populations, and
single assessments may provide only a limited impres-
sion of the overall parasite composition in a host [35].
In the present study, MOI increased with parasite den-
sity likely reflecting known threshold effects in the
detection of individual parasite clones [14,16,35]. The
observed increased multiplicity in clinical episodes of
malaria accords with some previous reports [14,39,40]
but contrasts with others [41,42]. Considering young age
and endemicity, the finding of the present study that
MOI is increased in malaria might result from the
recent acquisition of novel parasite clones (as reflected
by high MOI) which has been reported to increase the
probability of simultaneous clinical episodes [13,39].
Unexpectedly, MOI was lower in the rainy than in the
dry season. Despite possible distortion of results by
delayed onset of increased transmission, this contrasts
with previous studies [32,43,44] but is in line with a
study among Ghanaian infants in whom the variability
of circulating allelic populations was higher in the dry
season [5]. Although heterogeneity of malaria transmis-
sion, i.e. pockets of high transmission during the dry
season, might be involved in a comparatively high MOI
among children infected in the dry season, the actual
reasons for this are, however, obscure. Prior malaria epi-
sodes rather reduced the odds of current multiclonal
infection. However, the proportion of polyclonal infec-
tions did not differ between children with no previous
Figure 2 Distribution of MOI in Tamale and Afigya Sekyere.
Table 2 Multiplicity of infection and proportion of polyclonal infections according to previous IPTi with SP
Stratum No.
IPTI : placebo
mean MOI (median, range) P Proportion of polyclonal infections (%) P
Previous IPTi Previous Placebo Previous IPTi Previous Placebo
All 191 : 198 2.25 (2, 1-5) 2.33 (2, 1-6) 0.55 69.6 69.7 0.99
All microscopically positive 135 : 142 2.42 (2, 1-5) 2.38 (2, 1-6) 0.78 74.8 72.5 0.67
Afigya Sekyere 85 : 88 2.29 (2, 1-5) 2.31 (2, 1-6) 0.92 69.4 71.6 0.75
Tamale, all 106 : 110 2.22 (2, 1-5) 2.35 (2, 1-5) 0.49 69.8 68.2 0.80
Tamale, microscopically positive 50 : 54 2.64 (2.5, 1-5) 2.50 (2, 1-5) 0.59 84.0 74.1 0.22
Tamale, submicroscopic 56 : 56 1.84 (2, 1-5) 2.20 (2, 1-5) 0.17 57.1 62.5 0.56
P, comparisons by Mann-Whitney U test or c
2 test
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there was a trend for less polyclonal infections the
longer the last episode dated back (Table 3). Thus, con-
sidering that short-lived immune mechanisms evoked by
an infection and controlling (rather than eliminating)
multiple infections form the backbone of the concept of
premunition [6], this finding may reflect a temporal
decline in the ability to tolerate infection following an
episode. Lastly, multiplicity tended to be higher in
Tamale than in Afigya Sekyere although the opposite
was expected [7,16,17,43]. Possibly, a de facto higher
incidence of malaria has been missed in Tamale due to
the comparatively broader mesh of active follow-up.
Also, the use of artesunate for treatment there as com-
pared to long-acting artesunate-amodiaquine in Afigya
Sekyere might be involved in a more intense exposure.
Conclusions
IPTI-SP did not influence the multiplicity of P. falci-
parum up to the age of 15 months, although it reduced
t h ei n c i d e n c eo fm a l a r i ai nt h et w ot r i a l sb y2 4 %a n d
20%. This effect on malaria could largely be attributed
to a prophylactic effect of approximately one month
duration following treatment [21,22,24]. This resembles
the situation with ITNs, i.e., morbidity reduction and
absent effect on multiplicity [31] suggesting that imper-
fect or short-lived interventions allow for sufficient
exposure. Vice versa, the reduction of MOI following
RTS, S vaccination [29,30] might reflect its long-lasting
activity. IPTi-SP is debated controversially [24,45,46],
reasons including the absence of effect in areas of high
SP resistance [25], potential contributions to the emer-
gence of drug resistance [47], and clues for rebound
effects [19,21,22]. As for the latter, no evidence was
found suggesting that interference with multiplicity of
infection could be involved as has been proposed for
chemoprophylaxis [28]. The present study also high-
lights that MOI is influenced by various factors which
need to be taken into account when interpreting the
respective effects of interventions. The impact of IPTi
on multiplicity of infection and the development of
immunity using alternative, long-acting drugs which
likely will replace SP in the future [25] needs to be
defined.
Table 3 Univariate and multivariate associations with microscopically visible, polyclonal P. falciparum infections
Parameter No. Mean MOI (median,
range)
P Multivariate
analysis
a
Polyclonal infections
(%)
OR (95%CI) P Multivariate
analysis
b
bS EP aOR (95%CI) P
Previous IPTi-SP
No 142 2.38 (2, 1-6) 72.5 1 1
Yes 135 2.42 (2, 1-5) 0.78 -0.05 0.22 0.82 74.8 1.12 (0.64-
1.99)
0.67 0.93 (0.52-1.64) 0.79
Cohort
Tamale 104 2.57 (2, 1-5) 78.8 1 1
Afigya
Sekyere
173 2.30 (2, 1-6) 0.07 -0.67 0.26 0.01 70.5 0.64 (0.35-
1.18)
0.13 0.53 (0.28-1.03) 0.06
Current malaria episode
No 114 2.21 (2, 1-6) 64.0 1 1
Yes 163 2.53 (2, 1-5) 0.01 0.55 0.24 0.02 80.4 2.30 (1.29-
4.11)
0.002 2.35 (1.27-4.32) 0.006
Parasite density (/μL)
Log10 277 n.a. 0.049 0.24 0.13 0.07 n.a. 1.48 (1.08-
2.03)
0.01 1.38 (0.99-1.94) 0.06
Prior malaria episodes
None 72 2.50 (2, 1-5) 81.9 1 1
Any 205 2.37 (2, 1-6) 0.30 -0.19 0.26 0.46 70.7 0.53 (0.26-
1.09)
0.06 0.51 (0.25-1.05)
c,
d
0.07
Season
Dry season 92 2.49 (2, 1-5) 79.3 1 1
Rainy
season
185 2.36 (2, 1-6) 0.32 -0.77 0.27 0.004 70.8 1.58 (0.84-
3.01)
0.13 0.36 (0.18-0.72) 0.004
a, multivariate results are derived from non-parametric ordinal regression analysis including all listed parameters.
b, adjusted odds ratios (aORs) are derived from
logistic regression models including all other listed parameters; SE, standard error; OR, odds ratio; 95%CI, 95% confidence interval; n.a., not applicable;
c,
exchanging with number of previous malaria episodes (0-7): aOR, 0.98, 95%CI, 0.81-1.19; P = 0.84.
d, The proportion of polyclonal infections according to
arbitrarily set time periods from last previous episode was: <8 weeks (n = 65), 76.9%; 8-16 weeks (n = 62), 72.6%; >16 weeks (n = 78), 64.1%. Exchanging this
graded parameter with prior episodes per se yielded respective aORs (95%CIs) of 0.73 (0.30-1.78), 0.72 (0.29-1.76), and 0.32 (0.14-0.73).
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